Refine by
Muscle Mini Stimulator Articles & Analysis
16 news found
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium. CNK numbers are unique product code identifiers allocated by the Belgian Pharmaceutical Association (APB) for products and medicines commercially available from pharmacies throughout ...
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA-cleared, non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within selected managed care health systems. ...
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced data from an oral presentation at Neurocritical Care Society’s (NCS) 20th Annual Meeting held in San Antonio, Texas on October 17 – 21, 2022 on the possible role of gammaCore (nVNS) in the acute treatment of Traumatic Brain Injury (TBI). The presentation is being given by Dr. Afshin ...
Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announced that a peer-reviewed paper has recently been published in Sleep and Breathing. The analysis, published by University of California San Diego investigators Dr. Brandon Nokes, Professor Atul Malhotra, and other collaborators, is based on a post-hoc analysis ...
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder: A Double-Blind, Randomized, Sham-Controlled Pilot Study in the journal, Brain Stimulation. The ...
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is initiating an investigator-initiated study to assess the efficacy of gammaCore Sapphire non-invasive vagus nerve stimulation (nVNS) in patients with post-COVID syndrome. Post-COVID syndrome, also known as Long COVID, is a collection of symptoms that persist greater than 28 days ...
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more than 130 National Spine and Pain Centers (NSPC) affiliated locations across the United States for patients suffering from pain associated with different forms of ...
SAN CARLOS, California, July 22, 2021 — Galaxy Medical announced today that the 90 day remapping results of its ECLIPSE-AF study will be featured at the 2021 Stanford Biodesign New Arrhythmia Technologies Retreat on July 27th. Ante Ani, M.D., Electrophysiology Laboratory Director at University Clinical Hospital in Split, Croatia, and primary investigator of the study will deliver the ...
SAN CARLOS, California, April 22, 2021 — Galaxy Medical announced today that the acute results of its Europe-focused ECLIPSE-AF study will be featured during the upcoming EHRA Congress in a innovative Technology presentation on April 25th by Ante Ani , M.D., Electrophysiology Laboratory Director at University Clinical Hospital in Split, Croatia, and primary investigator of the study. The ...
SAN CARLOS, California, April 6, 2021 — Galaxy Medical (Galaxy) and Japan Lifeline (JLL) today announced an exclusive distribution agreement for the ALPHA1 ablation catheter in the United States, developed by Japan Lifeline for use with the Galaxy CENTAURI™ Pulsed Electric Field (PEF) System. Under the terms of the agreement, Galaxy will pursue US regulatory approval for ALPHA1 in ...
GALAXY’S PROPRIETARY CENTAURI™ SYSTEM ON TRACK FOR EU REGISTRATION AND US PIVOTAL TRIAL START LATER THIS YEAR; SHOWS BEST-IN-CLASS POTENTIAL. SAN CARLOS, California, March 16, 2021 — ATP, a leader in life science venture capital, announced today $18M in Series A financing for its portfolio company Galaxy Medical, Inc. The funds are being used to advance the development of ...
Applying non-invasive electrical stimulation to the expiratory abdominal muscles may reduce abdominal muscle atrophy and markedly reduce the number of days adult patients require mechanical ventilation – a potentially important finding for weaning ventilated patients, including seriously ill COVID-19 patients, and improving patient outcomes. Liberate Medical today announced the results of ...
Liberate Medical today announced that it has received Federal Drug Administration (FDA) Emergency Use Authorization for its VentFree™ Respiratory Muscle Stimulator, intended to be used to reduce disuse atrophy of the abdominal wall muscles, which may reduce the number of days adult patients require mechanical ventilation, including those patients with COVID-19. Reducing the time patients ...
Liberate Medical, a medical device company developing novel non-invasive electrical muscle stimulation devices to help patients with pulmonary conditions, today announced that it has received CE marking for its VentFree™ Respiratory Muscle Stimulator and ISO 13485 certification for its quality management system. The VentFree stimulator applies proprietary non-invasive electrical ...
Liberate Medical, a clinical-stage medical device company, developing novel electrical muscle stimulation devices that non-invasively address pulmonary conditions, today announced the results from its recently completed pilot trial of the VentFree Muscle Stimulator during an oral presentation at the American Thoracic Society International Conference (“ATS”) in Dallas, TX. ...
Liberate Medical, a clinical stage medical device company, focused on the development of novel non-invasive neuromuscular electrical stimulation devices to address pulmonary conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company’s VentFree muscle stimulator. The proposed indication for the device is preventing ...